Please assess the completion status of the following clinical trial:

Trial Title: Effects of Contrast Media on Subjects With Stable Reduced Renal Function Undergoing Contrast-Enhanced Computed Tomography

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females 18 years of age or older~* Subjects scheduled for a clinically indicated CECT requiring 40 grams of iodine (125 mL)~* Subjects have an abnormal screening SCr that results in a calculated eGFR of \< 60 mL/min/1.73 m2 using the MDRD formula and acute causes for an elevation in SCr have been excluded~* Subjects have stable reduced renal function which is defined as an abnormal screening SCr measurement with a \< 15% difference from the oldest historical SCr measurement obtained within the proceeding 1 week to 12 weeks~* Subjects must provide written consent and agree to abide by the site and study requirements~Exclusion Criteria:~* Subjects previously entered into this study~* Subjects on dialysis~* Subjects received any investigational drug within 30 days of contrast administration or participated in an investigational study within 30 days prior to study enrollment~* Subjects have undergone a procedure using iodinated or gadolinium contrast agent within 7 days prior to contrast administration, or is scheduled to receive additional doses of contrast agents during the 48-72 hour post-study contrast administration~* Subjects in acute renal failure or have one or more known causes of acute renal failure~* Subjects have known or suspected unstable renal function~* Subjects scheduled for a surgical intervention or other procedure within 72 hours after the contrast administration~* Subjects taking NSAIDs (with the exception of ASA) and/or any type of diuretics who cannot discontinue these drugs post contrast administration and hold all subsequent doses until the 48-72 hour post contrast SCr has been drawn~* Subjects taking aminoglycosides~* Subjects known to have an organ transplantation~* Subjects have severe congestive heart failure (Class III-IV)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Ioversol 320 mgI/mL
- 2 (Type: ACTIVE_COMPARATOR): Iodixanol 320 mgI/mL

Based on this trial design, predict the completion outcome and termination type (if applicable).